Here's what experiments TRISH is launching aboard Axiom Space's next mission. Photo via NASA

Houston's Translational Research Institute for Space Health, or TRISH, will launch six more experiments into space this spring aboard Axiom Space's Ax-2 mission, the organization announced this week.

The biomedical research conducted through TRISH, in consortium with CalTeach and MIT, will look into how space travel impacts everything from motion sickness to memory over the course of the mission's 10-day stint on the International Space Station.

The crew will consist of four astronauts: Commander Peggy Whitson (previously with NASA), Pilot John Shoffner and Mission Specialists Ali AlQarni and Rayyanah Barnawi. It's a historic team, bringing the first female private space crew commander and the first Saudi astronauts to the ISS.

“Insights gathered from this work improve our understanding of how the human body and mind respond to spaceflight, helping us to prepare future astronauts to remain safe and healthy during longer-duration missions," Dr. Dorit Donoviel, TRISH executive director and professor in the Center for Space Medicine at Baylor College of Medicine, says in a statement.

The six projects onboard the mission have been developed by researchers within TRISH as well as the University of Pennsylvania Perelman School of Medicine, Johns Hopkins University and Baylor College of Medicine. They aim to assess the following:

  • Spaceflight participants’ performance in memory, abstraction, spatial orientation, emotion recognition, risk decision making and sustained attention before and after the mission -Astronauts’ inner ears and eyes' response to motion before and after space travel and how this relates to motion sickness and nausea during launch and landing
  • The effects of spaceflight on the human body at the genomic level
  • Changes to the eyes and brain during spaceflight
  • Astronaut's sleep, personality, health history, team dynamics and immune-related symptoms
  • Sensorimotor abilities and changes in space and how this can impact astronauts' ability to stand, balance and have full body control on the moon

Some of this information will become part of TRISH’s Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program, which aims to boost human health on commercial space flights through its database. The program launched in 2021.

Ax-2 is Axiom's second all-private astronaut mission to the ISS and will launch out of NASA’s Kennedy Space Center in Florida aboard a SpaceX's Dragon spacecraft. Axiom was first established in 2016 with the goal of building the world's first commercial space station.

TRISH is also slated to launch nine experiments on board SpaceX's Polaris Dawn mission, which is now expected to launch this summer. The research aboard Polaris Dawn is intended to complement research supported by TRISH on the Inspiration4 all-civilian mission to orbit, which was also operated by SpaceX in 2021.

Axiom Space has announced its crew for its second commercial space launch. Image via Axiom

Houston space company announces historic flight crew

ready for liftoff

A Houston-based company is making history with its next commercial flight mission.

Axiom Space announced that Axiom Mission 2, or Ax-2, the second all-private mission to the International Space Station, will have members of the Kingdom of Saudi Arabia's national astronaut program aboard. It will also be the first private mission commanded by a woman: Peggy Whitson, Axiom's director of human spaceflight and former NASA astronaut.

“Axiom Space’s second private astronaut mission to the International Space Station cements our mission of expanding access to space worldwide and supporting the growth of the low-Earth orbit economy as we build Axiom Station,” says Michael Suffredini, president and CEO of Axiom Space, in a news release. “Ax-2 moves Axiom Space one step closer toward the realization of a commercial space station in low-Earth orbit and enables us to build on the legacy and achievements of the ISS, leveraging the benefits of microgravity to better life on Earth.”

Expected to launch this spring, it's the second ISS mission for the commercial aerospace company founded in 2016. Ax-2 Mission Specialists Ali Alqarni and Rayyanah Barnawi will be the first Saudi astronauts to visit the ISS after Axiom and the Kingdom of Saudi Arabia reached an agreement in 2022. With this mission, KSA will become only the sixth country to have two astronauts working on the ISS at the same time.

“This flight is an integral milestone of a comprehensive program aiming to train and qualify experienced Saudis to undertake human spaceflight, conduct scientific experiments, participate in international research, and future space-related missions contributing to the Kingdom’s Vision 2030,” reads a statement from the country.

Pilot John Shoffner, a businessman and aviator from Knoxville, Tennessee, with over 8,500 hours of flying under his belt, is the crew's fourth and final member.

A SpaceX Falcon 9 rocket will launch the Ax-2 crew aboard a SpaceX Dragon spacecraft to the ISS from NASA’s Kennedy Space Center in Florida, and they will spend 10 days on the mission. The mission is targeted for launch in the spring of 2023, and will be the first private space mission to include both private astronauts and astronauts representing foreign governments.

Whitson, a Rice university alum, will add to her deep resume, which also includes adding even more space time to the standing record for the longest cumulative time of any astronaut in the history of the U.S. space program.

“I am honored and excited to lead the Ax-2 crew and mission,” Whitson says in a statement. “The space station is a vital platform for all types of research. We at Axiom Space are committed to working with NASA to open the door for private citizens to contribute to and advance the groundbreaking research aboard the station, forging the path for us to operate, live and work abroad Axiom Station.”

Axiom aims to build its own commercial space station to launch in late 2025. Axiom’s first mission completed last April, and the company, deemed a unicorn with a $1 billion valuation, has raised $200 million, including a $130 million series B round in 2021.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.